Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06291883Phase 1Completed

Evaluation of KGR Prescriptions in Suppressing COVID-19 Infection.

Role: lead

NCT05943483Completed

To Establish the Traditional Chinese Medicine Based Intelligent Personal Health Care System

Role: lead

NCT05854680Completed

To Investigate the Metabolomics in the Subjects With Long Term Tai Chi Chuan Practice

Role: lead

NCT04974073Phase 3Completed

Development of PHY606 as Adjunct Therapy for Anemia Patients

Role: lead

All 4 trials loaded